tert-butyl 4-thioureidopiperidine-1-carboxylate | 849546-62-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl 4-thioureidopiperidine-1-carboxylate
• 英文别名: Tert-butyl 4-(carbamothioylamino)piperidine-1-carboxylate
• CAS: 849546-62-9
• 化学式: C₁₁H₂₁N₃O₂S
• mdl: MFCD26935995
• 分子量: 259.373
• InChiKey: KXHNTGAMNKYTRF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.818
• 拓扑面积：
  99.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-thioureidopiperidine-1-carboxylate 、 4,4'-二甲氧基苯酚酯 在 potassium hydroxide 作用下， 以 水 、 二甲基亚砜 为溶剂， 反应 0.17h， 生成 tert-butyl 4-(4,4-bis(4-methoxyphenyl)-5-oxo-2-thioxoimidazolidin-1-yl)-piperidine-1-carboxylate
  参考文献：
  名称：

  Evaluation of Aminohydantoins as a Novel Class of Antimalarial Agents

  摘要：

  Given the threat of drug resistance, there is an acute need for new classes of antimalarial agents that act via a unique mechanism of action relative to currently used drugs. We have identified a set of druglike compounds within the Tres Cantos Anti-Malarial Set (TCAMS) which likely act via inhibition of a Plasmodium aspartic protease. Structure-activity relationship analysis and optimization of these aminohydantoins demonstrate that these compounds are potent nanomolar inhibitors of the Plasmodium aspartic proteases PM-II and PM-IV and likely one or more other Plasmodium aspartic proteases. Incorporation of a bulky group, such as a cyclohexyl group, on the aminohydantion N-3 position gives enhanced antimalarial potency while reducing inhibition of human aspartic proteases such as BACE. We have identified compound 8p (CWHM-117) as a promising lead for optimization as an antimalarial drug with a low molecular weight, modest lipophilicity, oral bioavailability, and in vivo antimalarial activity in mice.

  DOI：

  10.1021/ml400412x
• 作为产物：
  描述：

  Tert-butyl 4-{[(phenylformamido)methanethioyl]amino}piperidine-1-carboxylate 在 水 、 potassium carbonate 、 sodium hydroxide 作用下， 以 乙醇 为溶剂， 以89 %的产率得到tert-butyl 4-thioureidopiperidine-1-carboxylate
  参考文献：
  名称：

  CN116768881

  摘要：

  公开号：

文献信息

• Thiazoline derivative and use of the same
  申请人：Kubo Keiji

  公开号：US20070010528A1

  公开（公告）日：2007-01-11

  A thiazoline derivative represented by Formula (I): wherein R is a cyclic hydrocarbon group which may be substituted, or a heterocyclic group which may be substituted; X is a bond or a divalent chain hydrocarbon group which may be substituted; X′ is a bond or —N(R 5 )—; Y is a divalent hydrocarbon group which may be substituted; Y′ is a bond or —C(═O)—; ring A is a nitrogen-containing heterocycle which may be substituted; Z 1 and Z 3 are each independently a bond or a divalent chain hydrocarbon group which may be substituted; Z 2 is a bond or —N(R 6 )—; and B is a group represented by the formula: which is useful as a therapeutic drug for thrombosis, is provided.

  提供一种由式（I）表示的噻唑啉衍生物：其中R是环烃基，可以被取代，或者是可以被取代的杂环基; X是键或二价链烃基，可以被取代; X'是键或-N(R5)-; Y是二价烃基，可以被取代; Y'是键或-C(═O)-; 环A是含氮杂环，可以被取代; Z1和Z3各自独立地是键或二价链烃基，可以被取代; Z2是键或-N(R6)-; B是下式表示的基团：该化合物可用作治疗血栓症的药物。
• THIAZOLINE DERIVATIVE AND USE OF THE SAME
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1669352A1

  公开（公告）日：2006-06-14

  A thiazoline derivative represented by Formula (I): wherein R is a cyclic hydrocarbon group which may be substituted, or a heterocyclic group which may be substituted; X is a bond or a divalent chain hydrocarbon group which may be substituted; X' is a bond or -N(R5)-; Y is a divalent hydrocarbon group which may be substituted; Y' is a bond or -C(=O)-; ring A is a nitrogen-containing heterocycle which may be substituted; Z1 and Z3 are each independently a bond or a divalent chain hydrocarbon group which may be substituted; Z2 is a bond or -N(R6)-; and B is a group represented by the formula: which is useful as a therapeutic drug for thrombosis, is provided.

  式 (I) 所代表的噻唑啉衍生物： 其中 R 是可被取代的环烃基或可被取代的杂环基；X 是键或可被取代的二价链烃基；X'是键或-N(R5)-；Y 是可被取代的二价烃基；Y'是键或-C(=O)-； 环 A 是可被取代的含氮杂环； Z1 和 Z3 各自独立地是键或可被取代的二价链烃基； Z2 是键或-N(R6)-； 以及 B 是由式表示的基团： 本发明提供了一种可作为血栓形成治疗药物的药物。
• US7534887B2
  申请人：——

  公开号：US7534887B2

  公开（公告）日：2009-05-19
• Evaluation of Aminohydantoins as a Novel Class of Antimalarial Agents
  作者：Marvin J. Meyers、Micky D. Tortorella、Jing Xu、Limei Qin、Zhengxiang He、Xingfen Lang、Wentian Zeng、Wanwan Xu、Li Qin、Michael J. Prinsen、Francis M. Sverdrup、Christopher S. Eickhoff、David W. Griggs、Jonathan Oliva、Peter G. Ruminski、E. Jon Jacobsen、Mary A. Campbell、David C. Wood、Daniel E. Goldberg、Xiaorong Liu、Yongzhi Lu、Xin Lu、Zhengchao Tu、Xiaoyun Lu、Ke Ding、Xiaoping Chen

  DOI：10.1021/ml400412x

  日期：2014.1.9

  Given the threat of drug resistance, there is an acute need for new classes of antimalarial agents that act via a unique mechanism of action relative to currently used drugs. We have identified a set of druglike compounds within the Tres Cantos Anti-Malarial Set (TCAMS) which likely act via inhibition of a Plasmodium aspartic protease. Structure-activity relationship analysis and optimization of these aminohydantoins demonstrate that these compounds are potent nanomolar inhibitors of the Plasmodium aspartic proteases PM-II and PM-IV and likely one or more other Plasmodium aspartic proteases. Incorporation of a bulky group, such as a cyclohexyl group, on the aminohydantion N-3 position gives enhanced antimalarial potency while reducing inhibition of human aspartic proteases such as BACE. We have identified compound 8p (CWHM-117) as a promising lead for optimization as an antimalarial drug with a low molecular weight, modest lipophilicity, oral bioavailability, and in vivo antimalarial activity in mice.
• CN116768881
  申请人：——

  公开号：——

  公开（公告）日：——